Tuesday, May 3, 2011
Agile Therapeutics Inc., of Princeton, N.J., presented and published Phase II data showing that AG200-15 delivers a daily estrogen dose of 30 mcg, is well tolerated and did not cause differences in ovulation in obese vs. nonobese women. The data were presented at the American College of Obstetricians and Gynecologists' 59th Annual Clinical Meeting and published in the journal Hormone Molecular Biology and Clinical Investigation.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.